Marksans Pharma Announcements
The Company has scheduled a conference call for analysts and investors on Friday, February 06, 2026 at 04:00 PM (IST) to discuss the Unaudited Financial...
22 Jan, 2026 | 04:35pm • Source: BSE
Certificate received from RTA under regulation 74(5) of SEBI (DP) regulations 2018, for the quarter ended December 31, 2025
13 Jan, 2026 | 03:31pm • Source: BSE
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and...
09 Jan, 2026 | 03:32pm • Source: BSE
Intimation for closure of trading window for the quarter ended December, 2025
26 Dec, 2025 | 11:49am • Source: BSE
Marksans Pharma Limited submits Transcript of Investors/analysts meet on Q2 FY26 Unaudited Financial Results held on November 14, 2025 at 05:00 pm.
21 Nov, 2025 | 12:13pm • Source: BSE
Marksans Pharma Limited''s wholly owned subsidiary Marksans Pharma Inc receives US FDA approval of its ANDA for Loperamide Hydrochloride 2mg tablets.
19 Nov, 2025 | 11:15am • Source: BSE
Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for its products from UK MHRA.
17 Nov, 2025 | 11:18am • Source: BSE
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding unaudited financial results for the quarter and half year ended September 30,...
17 Nov, 2025 | 10:14am • Source: NSE
Newspaper cuttings of unaudited financial results of the Company for the quarter and half year ended 30 September 2025 published in Business Standard (English) and...
17 Nov, 2025 | 09:44am • Source: BSE
Audio Recording upload intimation with respect to investors /analysts meet regarding Q2 FY26 unaudited financial results
14 Nov, 2025 | 07:56pm • Source: BSE
In line with the initiative of Central Vigilance Commission regarding observance of Vigilance Awareness Week 2025 by taking integrity pledge, Marksans appeal to all its...
10 Nov, 2025 | 02:32pm • Source: BSE
US FDA conducts cGMP inspection of Company''s 2nd manufacturing facility located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa with zero Form...
10 Nov, 2025 | 12:05pm • Source: BSE
Marksans Pharma Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK,...
05 Nov, 2025 | 09:35am • Source: NSE
Marksans Pharma Ltd''s wholly owned subsidiary Relonchem Ltd in the UK receives Marketing Authorisation for its product Exemestane 25mg film coated tablet from UK MHRA
05 Nov, 2025 | 09:10am • Source: BSE
Notification for all shareholders regarding the last stage of 100 days campaign.
03 Nov, 2025 | 12:13pm • Source: BSE
Marksans Pharma Limited has informed the Exchange about Schedule of a conference call for analysts and investors on Friday, November 14, 2025 at 05:00 PM...
31 Oct, 2025 | 12:50pm • Source: NSE
The Company has scheduled a conference call for analysts and investors on Friday, November 14, 2025 at 05:00 PM (IST) to discuss the Unaudited Financial...
31 Oct, 2025 | 11:41am • Source: BSE
Marksans Pharma Limited has informed the Exchange about voluntary ESG rating assigned by CFC Finlease Private Limited
27 Oct, 2025 | 10:41am • Source: NSE
CFC Finlease Private Limited , a SEBI lincensed ESG Rating Provider has voluntarily reviewed ESG rating on the Company, based on data available in public...
27 Oct, 2025 | 10:22am • Source: BSE
Marksans Pharma Limited''s wholly owned subsidiary Relonchem Limited receives Marketing Authorisation for it products from UK MHRA.
15 Oct, 2025 | 01:54pm • Source: BSE